53
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Spinal muscular atrophy linked to chromosome 5q (SMA) is a recessive, progressive, neuromuscular disorder caused by bi-allelic mutations in the SMN1 gene, resulting in motor neuron degeneration and variable presentation in relation to onset and severity. A prevalence of approximately 1–2 per 100,000 persons and incidence around 1 in 10,000 live births have been estimated with SMA type I accounting for around 60% of all cases. Since SMA is a relatively rare condition, studies of its prevalence and incidence are challenging. Most published studies are outdated and therefore rely on clinical rather than genetic diagnosis. Furthermore they are performed in small cohorts in small geographical regions and only study European populations. In addition, the heterogeneity of the condition can lead to delays and difficulties in diagnosing the condition, especially outside of specialist clinics, and contributes to the challenges in understanding the epidemiology of the disease. The frequency of unaffected, heterozygous carriers of the SMN1 mutations appears to be higher among Caucasian and Asian populations compared to the Black (Sub-Saharan African ancestry) population. However, carrier frequencies cannot directly be translated into incidence and prevalence, as very severe (death in utero) and very mild (symptom free in adults) phenotypes carrying bi-allelic SMN1 mutations exist, and their frequency is unknown.

          More robust epidemiological data on SMA covering larger populations based on accurate genetic diagnosis or newborn screening would be helpful to support planning of clinical studies, provision of care and therapies and evaluation of outcomes.

          Electronic supplementary material

          The online version of this article (doi:10.1186/s13023-017-0671-8) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references82

          • Record: found
          • Abstract: found
          • Article: not found

          Spinal muscular atrophy.

          Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness. It is caused by homozygous disruption of the survival motor neuron 1 (SMN1) gene by deletion, conversion, or mutation. Although no medical treatment is available, investigations have elucidated possible mechanisms underlying the molecular pathogenesis of the disease. Treatment strategies have been developed to use the unique genomic structure of the SMN1 gene region. Several candidate treatment agents have been identified and are in various stages of development. These and other advances in medical technology have changed the standard of care for patients with spinal muscular atrophy. In this Seminar, we provide a comprehensive review that integrates clinical manifestations, molecular pathogenesis, diagnostic strategy, therapeutic development, and evidence from clinical trials.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy.

            Homozygous deletion of the survival motor neuron 1 gene (SMN1) causes spinal muscular atrophy (SMA), the most frequent genetic cause of early childhood lethality. In rare instances, however, individuals are asymptomatic despite carrying the same SMN1 mutations as their affected siblings, thereby suggesting the influence of modifier genes. We discovered that unaffected SMN1-deleted females exhibit significantly higher expression of plastin 3 (PLS3) than their SMA-affected counterparts. We demonstrated that PLS3 is important for axonogenesis through increasing the F-actin level. Overexpression of PLS3 rescued the axon length and outgrowth defects associated with SMN down-regulation in motor neurons of SMA mouse embryos and in zebrafish. Our study suggests that defects in axonogenesis are the major cause of SMA, thereby opening new therapeutic options for SMA and similar neuromuscular diseases.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients.

              We analyzed clinical data of 569 patients in two combined series with childhood and juvenile proximal SMA. This cohort included only patients who had achieved the ability to sit unaided (type II and III SMA). The survival rate among 240 type II patients (who sat but never walked) was 98.5% at 5 years and 68.5% at 25 years. SMA III (n = 329) (those who walked and had symptoms before age 30 years) was subdivided into those with an onset before and after age 3 years (type IIIa, n = 195; SMA IIIb, n = 134). In patients with SMA III, life expectancy is not significantly less than a normal population. The probabilities of being able to walk at 10 years after onset was 70.3%, and at 40 years, 22.0% in SMA IIa. For SMA IIIb, 96.7% were walking 10 years after onset and 58.7% at 40 years. The subdivision of type III SMA was justified by the probability of being ambulatory depending on age at onset; the prognosis differed for those with onset before or after age 3 years. The data provide a reliable basis of the natural history of proximal SMA and support a classification system that is based primarily on age at onset and the achievement of motor milestones.
                Bookmark

                Author and article information

                Contributors
                ingrid.verhaart@ncl.ac.uk
                agata.robertson@ncl.ac.uk
                ian.wilson@ncl.ac.uk
                A.M.Aartsma-Rus@lumc.nl
                shona.cameron@ncl.ac.uk
                cynthia.jones@biogen.com
                epidemiologyassociatesllc@gmail.com
                +44-191-2418602 , hanns.lochmuller@ncl.ac.uk
                Journal
                Orphanet J Rare Dis
                Orphanet J Rare Dis
                Orphanet Journal of Rare Diseases
                BioMed Central (London )
                1750-1172
                4 July 2017
                4 July 2017
                2017
                : 12
                : 124
                Affiliations
                [1 ]ISNI 0000 0001 0462 7212, GRID grid.1006.7, John Walton Muscular Dystrophy Research Centre, , Institute of Genetic Medicine, Newcastle University, ; Newcastle upon Tyne, UK
                [2 ]ISNI 0000 0001 0462 7212, GRID grid.1006.7, Institute of Genetic Medicine, , Newcastle University, ; Newcastle upon Tyne, UK
                [3 ]Biogen MA Inc., Cambridge, USA
                [4 ]Epidemiology Associates LLC, Chapel Hill, USA
                [5 ]ISNI 0000 0001 0462 7212, GRID grid.1006.7, John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, , Institute of Genetic Medicine, Newcastle University, ; Central Parkway, Newcastle upon Tyne, NE1 3BZ UK
                Author information
                http://orcid.org/0000-0003-2324-8001
                Article
                671
                10.1186/s13023-017-0671-8
                5496354
                28676062
                51d0ff8c-f263-4331-88b0-299136ae0dbd
                © The Author(s). 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 15 May 2017
                : 13 June 2017
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100005614, Biogen;
                Categories
                Review
                Custom metadata
                © The Author(s) 2017

                Infectious disease & Microbiology
                spinal muscular atrophy,prevalence,incidence,carrier frequency,ethnic background

                Comments

                Comment on this article